menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Day One Reports Q4 and Full Year 2024 Financial Results

    GLOBENEWSWIRE

    Day One to Report Q4 & Full-Year 2024 Results on Feb 25

    GLOBENEWSWIRE

    Pediatric Brain Tumor Foundation Adds Dr. Samuel C. Blackman

    GLOBENEWSWIRE

    Day One Shares 2024 Ojemda™ Revenue And 2025 Priorities

    GLOBENEWSWIRE

    Day One to Present at 43rd J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    Day One Announces Dr. Samuel Blackman’s Retirement

    GLOBENEWSWIRE

    Day One to Participate in Piper Sandler Healthcare Conference

    GLOBENEWSWIRE

    Day One to Report Q3 2024 Financial Results Wednesday, Oct 30, 2024

    GLOBENEWSWIRE

    Day One Announces Oversubscribed $175.0 Million Private Placement

    GLOBENEWSWIRE

    Day One Reports Second Quarter 2024 Financial Results and Corporate Progress

    GLOBENEWSWIRE

    Ipsen And Day One Partner On Tovorafenib For Childhood Brain Tumor

    GLOBENEWSWIRE

    Ipsen Secures Ex-US Rights To Day One`s Pediatric Cancer Med For $111M

    FIERCE PHARMA

    Day One inks $1.2B biobucks pact for MabCare’s solid tumor ADC

    FIERCE PHARMA

    XOMA Receives $8.1M Milestone From Day One`s Voucher Sale

    GLOBENEWSWIRE

    Day One Announces Sale of Priority Review Voucher for $108 Million

    GLOBENEWSWIRE

    Day One Reports First Quarter 2024 Financial Results and Corporate Progress

    GLOBENEWSWIRE

    Pedia Brain Tumor Fdn Celebrates OJEMDA™ Approval for Pedia Brain Tumor

    GLOBENEWSWIRE

    Day One drug for common childhood brain tumor approved by FDA

    FDA

    Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval

    PRESS RELAESE

    Day One`s Tovorafenib Gets FDA Approval For Pediatric pLGG

    GLOBENEWSWIRE

    Day One Reports Fourth Quarter and Full Year 2023 Financial Results

    GLOBENEWSWIRE

    Day One Announces Two New Appointments to Board of Directors

    GLOBENEWSWIRE

    Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

    GLOBENEWSWIRE

    Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference

    GLOBENEWSWIRE

    Day One Reports Third Quarter 2023 Financial Results and Corporate Progress

    GLOBENEWSWIRE

    Day One Announces FDA Acceptance of NDA for Tovorafenib in pLGG

    GLOBENEWSWIRE

    Day One Announces Updated FIREFLY-1 Data for Tovorafenib

    GLOBENEWSWIRE

    Day One jets off with Sprint`s VRK1 program for up to $316M

    FIERCE BIOTECH

    Day One Reports Second Quarter 2023 Financial Results and Corporate Progress

    GLOBENEWSWIRE

    Day One Announces Closing of Public Offering

    GLOBENEWSWIRE

    Day One goes to the market for $150M as biotech kicks off NDA request

    ENDPTS

    Day One Announces Proposed Public Offering of Common Stock

    GLOBENEWSWIRE

    Day One Announces Pricing of Public Offering of Common Stock

    GLOBENEWSWIRE

    Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101)

    GLOBENEWSWIRE

    Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference

    GLOBENEWSWIRE

    Day One Announces TovorafenibData and Abstracts to be Presented at ASCO

    GLOBENEWSWIRE

    Day One Reports First Quarter 2023 Financial Results and Corporate Progress

    GLOBENEWSWIRE

    Day One Announces Abstracts Accepted for Presentation at the 2023 ASCO

    GLOBENEWSWIRE

    Day One Announces Upcoming Presentation at 19th EADO Congress

    GLOBENEWSWIRE

    Day One Reports Fourth Quarter and Full Year 2022 Financial Results

    GLOBENEWSWIRE

    Day One to Participate in the Cowen 43rd Annual Health Care Conference

    GLOBENEWSWIRE

    Day One Announces Data from Phase 2 FIREFLY-1 Trial for Tovorafenib

    GLOBENEWSWIRE

    Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    Day One Announces Cooperative R&D Agreement with NCI of Tovorafenib

    GLOBENEWSWIRE

    Day One Reports Second Quarter 2022 Financial Results and Corporate Progress

    GLOBENEWSWIRE

    Day One to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

    GLOBENEWSWIRE

    Day One Announces Closing of UPO and Full Exercise of the Underwriters` Option

    GLOBENEWSWIRE

    Day One spends day 2 hitting up public markets for $150M

    FIERCEBIOTECH

    Day One Announces Proposed Public Offering of Common Stock

    GLOBENEWSWIRE

    Day One Announces Pricing of Upsized Public Offering of Common Stock

    GLOBENEWSWIRE

    Day One`s share price doubles on brain tumor drug data

    FIERCEBIOTECH

    Day One`s Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib

    GLOBENEWSWIRE

    Day One Begins Dosing in PIb/II Combination Study with Tovorafenib

    GLOBENEWSWIRE

    Day One Biopharmaceuticals Cut to “Sell” at Zacks Investment Research

    DEFENSE WORLD

    Day One Reports First Quarter 2022 Financial Results

    GLOBENEWSWIRE

    Day One to Present at the 21st Annual Needham Virtual Healthcare Conference

    GLOBENEWSWIRE

    Day One Reports Q4 and FY 2021 Financial Results

    GLOBENEWSWIRE

    Day One Reports Second Quarter 2021 Financial Results and Corporate Progress

    GLOBENEWSWIRE

    Day One Reports Second Quarter 2021 Financial Results and Corporate Progress

    GLOBENEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.